Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients

HIV 患者使用医用大麻的行为经济学分析

基本信息

  • 批准号:
    8228758
  • 负责人:
  • 金额:
    $ 52.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-15 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): State laws that allow medical marijuana use, including the Michigan Medical Marihuana Program (MMMP), create policy tension due to a paucity of scientific data about factors that influence: marijuana use patterns, abuse potential, decisions to seek/renew medical certification, impact of marijuana use on HIV risk behaviors, and health outcomes. This proposal will address these knowledge gaps by studying marijuana-using persons living with HIV/AIDS (PLWHAs) in Michigan's largest HIV primary care clinic (Detroit, 1700 patients) with a prospective mixed-method approach, as described in these Specific Aims: Aim 1. In 120 marijuana-using PLWHAs (certified medical users, non-certified therapeutic users, and recreational users; 40/group), we will (A) use behavioral economic simulations to evaluate marijuana demand sensitivity to experimental manipulation of unit price and income; and (B) determine whether marijuana price elasticity, cross-price elasticity with other drugs/therapies, and income elasticity differ across marijuana user groups. Aim 2. In a subset of 36 marijuana-using PLWHAs (certified medical, non-certified therapeutic, and recreational users; 12/group from Aim 1), conduct a laboratory-based, double blind, placebo-controlled, marijuana smoking evaluation (cumulative 0, 4, 8 and 12 puffs from 3.5% delta 9-THC cigarettes). We will (A) determine whether marijuana dose-effect profiles for symptom relief and abuse liability differ between marijuana-using groups; (B) compare smoked marijuana demand across groups; and (C) compare intensity of experimental ("gold standard") and naturalistic smoking effects. Aim 3. In the same 120 marijuana-using PLWHAs as Aim 1, use chart review, urinalysis, and interviews to measure prospectively at baseline, and at quarterly intervals for one year, clinical factors that are hypothesized to influence marijuana use and medical certification: socioeconomic changes, physical and mental health, substance use, criminal justice involvement, acute care utilization, HIV risk-transmission behaviors, and reasons for marijuana use. We will use clinical data alone and combined with simulated marijuana demand (Aim 1) and smoked marijuana responses (Aim 2) to predict longitudinal patterns of marijuana and alternative therapy use. Aim 4. Determine whether prevalence of certified medical marijuana use, non-certified therapeutic use, and recreational use in the 120-patient prospective sample generalizes to the entire HIV clinic. We will survey a random sample of 300 PLWHAs to (A) determine whether marijuana use patterns are representative within this large urban clinic located in the area with disproportionally high HIV prevalence, and (B) compare characteristics of this sample to prior cross-sectional survey data. At the conclusion of this project, we anticipate that (1) these data will reveal distinct patterns within this population; (2) we will have achieved a more sophisticated understanding of medical marijuana use, and (3) we will be able to predict which subsets of HIV patients are likely to benefit or be harmed. These findings will be disseminated to patients, providers and society to promote public health and informed policy debate. PUBLIC HEALTH RELEVANCE: Implementation of state laws that allow medical marijuana use - including the Michigan Medical Marihuana Program (MMMP) - create a significant policy problem because we lack systematic scientific data concerning factors that influence: marijuana use patterns, abuse potential, decisions to seek or renew medical certification, impact of marijuana use on HIV transmission behaviors, and health outcomes. The overall goal of this proposal is to address these knowledge gaps by studying subgroups of marijuana-using HIV patients (certified medical users, non-certified therapeutic users and recreational users) in Michigan's largest HIV primary care clinic (Detroit) with a prospective mixed-method approach that uses behavioral-economic simulations of marijuana demand, laboratory-based psychopharmacological assessment, longitudinal health monitoring, and probability survey procedures.
描述(由申请人提供):允许使用医用大麻的州法律,包括密歇根州医用大麻计划(MMMP),由于缺乏有关影响因素的科学数据而造成政策紧张:大麻使用模式,滥用潜力,寻求/更新医疗认证的决定,大麻使用对艾滋病毒风险行为的影响,以及健康结果。该提案将通过研究密歇根州最大的艾滋病毒初级保健诊所(底特律,1700名患者)的大麻使用者艾滋病毒/艾滋病感染者(PLWHA)来解决这些知识差距,具体目标:目标1中描述了前瞻性混合方法。在120名使用大麻的PLWHA(认证的医疗使用者,非认证的治疗使用者和娱乐使用者; 40/组)中,我们将(A)使用行为经济学模拟来评估大麻需求对实验操纵单价和收入的敏感性;(B)确定大麻价格弹性,与其他药物/治疗的交叉价格弹性以及收入弹性是否在大麻使用者群体中存在差异。目标2.在36名使用大麻的PLWHA(经认证的医疗、非认证的治疗和娱乐使用者;目标1中的12名/组)的子集中,进行基于实验室的、双盲、安慰剂对照的大麻吸烟评估(从3.5% δ 9-THC香烟中累积0、4、8和12次抽吸)。我们将(A)确定大麻使用组之间症状缓解和滥用倾向的大麻剂量效应曲线是否不同;(B)比较各组之间吸食大麻的需求;(C)比较实验(“金标准”)和自然主义吸烟效应的强度。目标3。在与目标1相同的120名使用大麻的PLWHA中,使用图表审查,尿液分析和访谈在基线时前瞻性地测量,并在一年内每季度测量一次,假设影响大麻使用和医疗认证的临床因素:社会经济变化,身心健康,物质使用,刑事司法参与,急性护理利用,艾滋病毒风险传播行为,以及吸食大麻的原因我们将单独使用临床数据,并结合模拟大麻需求(目标1)和吸食大麻的反应(目标2)来预测大麻和替代疗法使用的纵向模式。目标4。确定120例患者前瞻性样本中经认证的医用大麻使用、未经认证的治疗性使用和娱乐性使用的流行率是否普遍适用于整个HIV诊所。我们将调查300名PLWHA的随机样本,以(A)确定大麻使用模式是否具有代表性,在这个大型城市诊所位于艾滋病毒流行率高的地区,和(B)比较这个样本的特点,以前的横断面调查数据。在这个项目结束时,我们预计(1)这些数据将揭示这一人群中的独特模式;(2)我们将对医用大麻的使用有更深入的了解,(3)我们将能够预测哪些HIV患者亚群可能受益或受到伤害。这些研究结果将传播给患者,提供者和社会,以促进公共卫生和知情的政策辩论。 公共卫生关系:实施允许医用大麻使用的州法律-包括密歇根州医用大麻计划(MMMP)-产生了一个重大的政策问题,因为我们缺乏有关影响因素的系统科学数据:大麻使用模式,滥用潜力,寻求或更新医疗认证的决定,大麻使用对艾滋病毒传播行为的影响,以及健康结果。该提案的总体目标是通过研究使用大麻的艾滋病毒患者亚组来解决这些知识差距(认证的医疗用户,非认证的治疗用户和娱乐用户)在密歇根州最大的艾滋病毒初级保健诊所(底特律)与前瞻性混合方法的方法,使用大麻需求的行为经济模拟,基于实验室的心理药理学评估,纵向健康监测,和概率调查程序。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark K Greenwald其他文献

Mark K Greenwald的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark K Greenwald', 18)}}的其他基金

Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD)
开发cebranopadol,一种有效的双重MOP/NOP激动剂,用于治疗阿片类药物使用障碍(OUD)
  • 批准号:
    10759100
  • 财政年份:
    2023
  • 资助金额:
    $ 52.68万
  • 项目类别:
Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care
规划多层次干预措施以减少艾滋病毒预防和护理中的药物使用耻辱
  • 批准号:
    10669764
  • 财政年份:
    2021
  • 资助金额:
    $ 52.68万
  • 项目类别:
Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients
HIV 患者使用医用大麻的行为经济学分析
  • 批准号:
    8331559
  • 财政年份:
    2011
  • 资助金额:
    $ 52.68万
  • 项目类别:
Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients
HIV 患者使用医用大麻的行为经济学分析
  • 批准号:
    8484810
  • 财政年份:
    2011
  • 资助金额:
    $ 52.68万
  • 项目类别:
Human Laboratory Model of Cocaine Treatment: Behavioral Economic Analysis
可卡因治疗的人体实验室模型:行为经济学分析
  • 批准号:
    7894996
  • 财政年份:
    2009
  • 资助金额:
    $ 52.68万
  • 项目类别:
Human Laboratory Model of Cocaine Treatment: Behavioral Economic Analysis
可卡因治疗的人体实验室模型:行为经济学分析
  • 批准号:
    7697838
  • 财政年份:
    2009
  • 资助金额:
    $ 52.68万
  • 项目类别:
Development and Use of rtfMRI for Self-control of Nicotine Craving
rtfMRI 的开发和使用用于自我控制尼古丁渴望
  • 批准号:
    7588461
  • 财政年份:
    2008
  • 资助金额:
    $ 52.68万
  • 项目类别:
Development and Use of rtfMRI for Self-control of Nicotine Craving
rtfMRI 的开发和使用用于自我控制尼古丁渴望
  • 批准号:
    8087596
  • 财政年份:
    2008
  • 资助金额:
    $ 52.68万
  • 项目类别:
Development and Use of rtfMRI for Self-control of Nicotine Craving
rtfMRI 的开发和使用用于自我控制尼古丁渴望
  • 批准号:
    8104244
  • 财政年份:
    2008
  • 资助金额:
    $ 52.68万
  • 项目类别:
Development and Use of rtfMRI for Self-control of Nicotine Craving
rtfMRI 的开发和使用用于自我控制尼古丁渴望
  • 批准号:
    8282904
  • 财政年份:
    2008
  • 资助金额:
    $ 52.68万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 52.68万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了